A Study With CIT-013 in HS Patients

The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

NCT Number	NCT06993233
Lead Sponsor	Citryll BV
Conditions	Hidradenitis Suppurativa (HS)
Enrollment	96 participants
Start Date	2025-10-31
Primary Completion	2027-04 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-22